Essential Partners
AGIO icon

Essential Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Essential Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19.9K Buy
599
+42
+8% +$1.47K 0.01% 912
2026
Q2 		$20.7K Buy
557
+552
+11,040% +$16.7K 0.01% 890
2026
Q1 		$169 Hold
5
– – ﹤0.01% 2639
2025
Q4 		$136 Sell
5
-110
-96% -$3.86K ﹤0.01% 2508
2025
Q3 		$4.62K Hold
115
– – ﹤0.01% 1454
2025
Q2 		$3.82K Buy
+115
New +$3.49K ﹤0.01% 1132

Other funds holding AGIO

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners's AGIO Position: Q3 2026 in Review

Essential Partners increased its Agios Pharmaceuticals (AGIO) stake by 7.5% in Q3 2026, buying an estimated $1.47K and bringing the position to 599 shares worth $19.9K. The position accounts for 0.01% of the portfolio, ranked #912.

Essential Partners first reported a position in AGIO in Q2 2025 and has held it in 6 quarters since. The position peaked at $20.7K in Q2 2026. 20 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

  • Essential Partners held 599 shares of Agios Pharmaceuticals worth $19.9K as of Q3 2026.
  • Essential Partners bought 42 Agios Pharmaceuticals shares in Q3 2026, an estimated $1.47K.
  • Agios Pharmaceuticals made up 0.01% of Essential Partners's portfolio in Q3 2026, its #912 holding.
  • Essential Partners first reported a position in Agios Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Agios Pharmaceuticals position peaked at $20.7K in Q2 2026.
  • 20 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.